A higher complete remission (CR) rate was observed in patients with
acute myeloid leukemia (AML) who, on a prior randomized study of induction
therapy, received
gemtuzumab ozogamicin (GO) plus
interleukin-11 (IL-11) rather than GO alone. An adaptive randomized phase III study of the addition of
IL-11 to
idarubicin and
cytarabine (IA) induction in 100 patients >/=50 years of age with AML or high-risk
myelodysplastic syndrome (MDS) was conducted. Median patient age was 67 years (range 50-82). Twenty-four of the 45 (53%) patients randomized to IA plus
IL-11 achieved CR. Eight (33%) subsequently relapsed, 4 (17%) died in CR; median
time to treatment failure (TTF) was 37 weeks. Twenty-nine of the 55 (53%) patients treated without
IL-11 achieved CR. Eight (28%) subsequently relapsed, 2 (7%) died in CR; median TTF was 46 weeks. Median overall survivals were 21 and 59 weeks for the IA plus
IL-11 and IA cohorts, respectively (p=0.271, log rank test; 0.435, Gehan-Breslow test). Ten episodes of the following grade 3 or 4 cardiopulmonary toxicities were observed in patients receiving IA plus
IL-11, 12 such episodes in those receiving IA alone:
atrial fibrillation,
pleural effusions,
myocardial infarction,
bradycardia or
hypotension. Two patients in each arm experienced grade 3 peripheral
edema. There was no significant difference in incidence of any grade 3 or 4 adverse event, including
thrombocytopenia, between treatment arms. There was no significant impact on CR rates, TTF, survival, or toxicity of adding an
IL-11 regimen to IA induction in patients >/=50 years of age with AML.